---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-22-000087"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2022-10-18T23:59:59+00:00"
generated_at: "2026-06-23T03:02:38.522280+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio doses first patient with ITIL-306 CoStAR-TIL in Phase 1 NSCLC trial

## Summary
- First patient dosed in Phase 1 study of ITIL-306, a CoStAR-engineered TIL therapy targeting FRα in non-small cell lung cancer.
- ITIL-306 designed to enhance TIL activity in tumor microenvironment and eliminate need for high-dose IL-2.
- Initial clinical data from dose escalation cohorts expected in 2023.
- Phase 1 open-label multicenter study also includes ovarian and renal cell carcinoma patients.

## SEC filing metadata
- accession: 0001789769-22-000087
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2022-10-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000087/0001789769-22-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000087/til-20221018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-22-000087
- JSON: https://secwatch.observer/filing/0001789769-22-000087.json
- Plain text: https://secwatch.observer/filing/0001789769-22-000087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.